Premature Ejaculation Treatment Global Market Report 2024

The premature ejaculation treatment market size has grown strongly in recent years. It will grow from $3.53 billion in 2023 to $3.88 billion in 2024 at a compound annual growth rate (CAGR) of 10%. The growth observed in the historical period can be attributed to various factors, including the increasing prevalence of premature ejaculation, a rise in awareness and reduced stigma surrounding the condition, efforts in physician and patient education, evolving societal attitudes toward sexual health, the expansion of telemedicine services, and initiatives from the pharmaceutical industry.

The premature ejaculation treatment market size is expected to see strong growth in the next few years. It will grow to $5.62 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The anticipated growth in the forecast period can be attributed to a continued focus on sexual health, the adoption of individualized treatment approaches, global efforts to address sexual dysfunction, the proliferation of online health platforms and apps, and increased openness in healthcare discussions. Major trends expected in the forecast period include a rise in behavioral and psychosexual therapies, the development of novel topical therapies, advancements in pharmacological treatments, the integration of telemedicine and online platforms, a focus on patient education and counseling, and ongoing research on novel mechanisms of action for premature ejaculation treatment.

The growing prevalence of sexual disorders is anticipated to drive the growth of the premature ejaculation treatment market. Sexual disorders or dysfunctions encompass difficulties faced by both men and women during any phase of regular intimate activity. Premature ejaculation, a specific sexual disorder, is addressed through treatment options involving medications or therapeutic approaches. For example, a November 2021 survey of 2,000 UK adults conducted by Pharmacy Direct GB, a UK-based online pharmacy, revealed that approximately 48% of UK residents reported experiencing erectile dysfunction, representing around 16.5 million individuals. The National Health Service spent over $17.9 million (£13 million) on Erectile Dysfunction treatment prescriptions in 2021. Additionally, a July 2022 survey of 1,000 men across the UK by Click2Pharmacy, a UK-based provider of local prescription treatment services, found that around 58.2% experienced erectile dysfunction in the UK, with 3 in 4 men between the ages of 25 and 34 experiencing erectile dysfunction in 2022. Thus, the increasing prevalence of sexual disorders is contributing to the growth of the premature ejaculation treatment market.

The rise in awareness about sexual health is expected to further fuel the growth of the premature ejaculation treatment market. Sexual health encompasses holistic well-being, including the physical, emotional, cognitive, and social dimensions of one's sexuality. Increased awareness about sexual health is crucial for effective premature ejaculation treatment, fostering understanding, communication, and informed decision-making. In October 2023, the UK Health Security Agency, a UK-based government agency, reported a notable increase in consultations at sexual health services (SHSs), reaching a total of 4,394,404 in 2022. This represented an 8.2% rise from the previous year, with the count standing at 4,059,608 in 2021. Therefore, the growing awareness about sexual health is playing a significant role in propelling the growth of the premature ejaculation treatment market.

A lack of effective treatment options is anticipated to impede the growth of the premature ejaculation treatment market. Inadequate treatment choices may lead to suboptimal outcomes for individuals dealing with premature ejaculation, hampering their ability to achieve effective management and control of the condition. For example, a May 2023 report from the National Center for Biotechnology Information, a US-based government library of medicine, indicated that premature ejaculation treatment success rates ranged from 30% to 70%, with frequent relapses requiring lifelong therapy for some men. Consequently, the absence of effective treatment options is a limiting factor for the growth of the premature ejaculation treatment market.

Key companies in the premature ejaculation treatment market are focusing on developing new solutions, such as delay sprays, to drive revenues. Delay sprays are specially formulated products applied to the penis before sexual activity to help men last longer during intercourse. They work by temporarily dulling penis nerves, reducing penis sensitivity, and delaying ejaculation. For instance, in August 2023, Maude, a US-based sexual wellness company, introduced Stay, a delay spray explicitly designed to address premature ejaculation. This product contains 10% lidocaine, a fast-evaporating local anesthetic that reduces sensitivity in the male genital region. Stay is compatible with both latex and polyisoprene condoms, various lubricants, and devices. It is vegan-friendly, fragrance-free, and free from sulfates, silicones, and parabens.

In November 2021, ANI Pharmaceuticals Inc., a US-based pharmaceutical company, acquired Novitium Pharma LLC for an undisclosed amount. This acquisition aimed to enhance ANI Pharmaceuticals' capabilities in research and development and increase generic manufacturing capacity. Novitium Pharma LLC is a US-based provider of selective serotonin reuptake inhibitors (SSRIs), including paroxetine used for premature ejaculation.

Major companies operating in the premature ejaculation treatment market report are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Menarini Group, Lupin Limited., Amneal Pharmaceuticals Inc., Mankind Pharma Ltd., Cipla Limited, Alembic Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., ANI Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Vivus Inc., Absorption Pharmaceuticals LLC, Innovus Pharmaceuticals Inc., Sunrise Pharmaceuticals Inc., Solco Healthcare US LLC, Apricus Biosciences Inc., Regent Pacific Group Limited, Endurance RP Ltd.

North America was the largest region in the premature ejaculation treatment market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the premature ejaculation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the premature ejaculation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Premature ejaculation treatment involves the use of medication or therapy to address and manage the symptoms of premature ejaculation. This type of treatment encompasses the application of medicines or therapeutic interventions to tackle and alleviate premature ejaculation.

The main types of premature ejaculation treatments include antidepressants (SSRIs), phosphodiesterase-5 inhibitors, topical anesthetics, analgesics, and other therapeutic options. Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medications commonly used for treating depression. These treatments can be administered orally or topically and may be obtained through retail or direct-to-consumer channels. Various applications for premature ejaculation treatments include hospitals, retail pharmacies, online pharmacies, and other healthcare settings.

The premature ejaculation treatment market research report is one of a series of new reports that provides premature ejaculation treatment market statistics, including premature ejaculation treatment industry global market size, regional shares, competitors with a premature ejaculation treatment market share, detailed premature ejaculation treatment market segments, market trends and opportunities, and any further data you may need to thrive in the premature ejaculation treatment industry. This premature ejaculation treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The premature ejaculation treatment market includes revenues earned by entities by providing services such as psychological therapy, cognitive-behavioral therapy and behavioral therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The premature ejaculation treatment market consists of sales of medications, inhibitors and drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.